Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcellx Inc (ACLX)
NASDAQ:ACLX
Holding ACLX?
Track your performance easily
ACLX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$46.42 - $107.37
Previous Close$87.22
Volume165.97K
Average Volume (3M)537.70K
Market Cap
$4.75B
Enterprise Value$4.23B
Total Cash (Recent Filing)$574.25M
Total Debt (Recent Filing)$65.33M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Mar 20, 2025EPS Estimate
-$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding54,074,670
10 Day Avg. Volume597,698
30 Day Avg. Volume537,703
Standard Deviation0.21
R-Squared0.00408
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)9.77
Price to Sales (P/S)30.40
Price to Cash Flow (P/CF)38.60
P/FCF Ratio41.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue27.13
Enterprise Value/Gross Profit38.32
Enterprise Value/Ebitda-145.81
Forecast
1Y Price Target
$109.64Price Target Upside25.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Arcellx Inc News
Bulls Say, Bears Say
Bulls Say
Clinical Trials And EfficacyThe outcomes from the Phase 2 iMMagine-1 trial support anito-cel's 'best-in-class' profile, showcasing impressive efficacy and safety data with no cases of parkinsonism or Guillain-Barré syndrome among more than 140 patients.
Financial PerformanceArcellx ended the quarter with $678M in cash, equivalents, and marketable securities, ensuring financial stability and a strong cash runway into 2027.
Market OpportunitiesArcellx retains 100% of the rights to anito-cel in autoimmune diseases, including myasthenia gravis, which represents a multi-billion dollar market potential.
Bears Say
Adverse EventsCARVYKTI has shown 10-12% delayed neurotoxicity in real-world and CARTITUDE-1 studies, a potentially serious safety issue that physicians must contend with.
Safety ConcernsThree deaths occurred due to adverse events, highlighting potential risks despite the positive outcomes.
Supply Chain IssuesLegend / JnJ changed CARVYKTI release specifications during development, contributing to higher manufacturing failure rates, and exacerbating the supply shortage for JnJ/Legend's Carvykti.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ACLX FAQ
What was Arcellx Inc’s price range in the past 12 months?
Arcellx Inc lowest stock price was $46.42 and its highest was $107.37 in the past 12 months.
What is Arcellx Inc’s market cap?
Currently, no data Available
When is Arcellx Inc’s upcoming earnings report date?
Arcellx Inc’s upcoming earnings report date is Mar 20, 2025 which is in 119 days.
How were Arcellx Inc’s earnings last quarter?
Arcellx Inc released its earnings results on Nov 07, 2024. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.31 by -$0.17.
Is Arcellx Inc overvalued?
According to Wall Street analysts Arcellx Inc’s price is currently Undervalued.
Does Arcellx Inc pay dividends?
Arcellx Inc does not currently pay dividends.
What is Arcellx Inc’s EPS estimate?
Arcellx Inc’s EPS estimate is -$0.56.
How many shares outstanding does Arcellx Inc have?
Arcellx Inc has 54,074,670 shares outstanding.
What happened to Arcellx Inc’s price movement after its last earnings report?
Arcellx Inc reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.31. Following the earnings report the stock price went up 3.933%.
Which hedge fund is a major shareholder of Arcellx Inc?
Among the largest hedge funds holding Arcellx Inc’s share is Perceptive Advisors LLC. It holds Arcellx Inc’s shares valued at 325M.
---
Arcellx Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$109.64 (25.27% Upside)
$109.64 (25.27% Upside)
Blogger Sentiment
Bullish
ACLX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 247.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 15.2%
Last 30 Days ▲ 15.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.75%
12-Months-Change
Fundamentals
Return on Equity
-10.79%
Trailing 12-Months
Asset Growth
24.53%
Trailing 12-Months
Company Description
Arcellx Inc
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.
---
ACLX Stock 12 Month Forecast
Average Price Target
$109.64
▲(25.27% Upside)
Technical Analysis
Best Analysts Covering ACLX
1 Year
1 Year Success Rate
14/14 ratings generated profit
1 Year Average Return
+66.49%
reiterated a buy rating 17 days ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +66.49% per trade.
---